Repaglinide as monotherapy in Type 2 diabetes

Experimental and Clinical Endocrinology and Diabetes

Volumn 107, Issue SUPPL. 4, 1999, Pages

  Gomis, Ramon ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Glycaemic control; Monotherapy; Repaglinide; Type 2 diabetes

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; ORAL ANTIDIABETIC AGENT; REPAGLINIDE; SULFONYLUREA;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EXERCISE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032869657     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0029-1212168     Document Type: Conference Paper

References (10)

1. Fuhlendorff J, Rorsman P, Kofod H, Brand CL, Rolin B, MacKay P, Shymko R, Carr RD: Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 47: 345-351, 1998
2. Goldberg RB, Brodows RG, Damsbo P, for the Repaglinide Study Group: A randomized, placebo-controlled trial of repaglinide in the treatment of Type 2 diabetes [abstract]. Diabetes 47 (Suppl 1): A98, 1998
3. Hosker JP, Rudenski AS, Burnett MA, Matthews DR, Turner RC: Similar reduction of first-and second-phase beta-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy. Metabolism 38: 767-772, 1989
4. Marbury TC, Hatorp V: Pharmacokinetics of repaglinide after single and multiple doses in patients with renal impairment compared with normal healthy volunteers [abstract]. Diabetes 47 (Suppl 1): A357, 1998
5. Oliver S, Ahmad S, Windfeld K, Hatorp V: Pharmacokinetics and bio-availability of repaglinide, a new OHA for patients with NIDDM [abstract]. Diabetologia 40 (Suppl 1): A320, 1997
6. O'Meara NM, Shapiro ET, Van Cauter E, Polonsky KS: Effect of glyburide on beta cell responsiveness to glucose in non-insulin-dependent diabetes mellitus. Am J Med 89: 11S-16S, discussion 51S-53S, 1990
7. Schmitz O, Damsbo P: Improved glycaemic control with repaglinide in NIDDM with 3 times daily meal related dosing [abstract]. Diabetes 47 (Suppl 1): A98, 1998
8. Schwartz SL, Goldberg RB, Strange P: Repaglinide in Type 2 diabetes: a randomised, double-blind, placebo-controlled, dose-response study [abstract]. Diabetes 47 (Suppl 1): A98, 1998
9. Tronier B, Marbury TC, Damsbo P, Windfeld K: A new oral hypoglycaemic agent, repaglinide, minimises risk of hypoglycaemia in well-controlled NIDDM patients [abstract]. Diabetologia 38 (Suppl 1): A752, 1995
10. 14C-repaglinide during non-labelled repaglinide multiple dosing. Diabetes 47 (Suppl 1): A355, 1998